Panitumumab

Therapeutic indications

Panitumumab is indicated for:

Wild-type RAS metastatic colorectal cancer (mCRC)

Population group: only adults (18 years old or older)

Panitumumab is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):

  • in first-line in combination with FOLFOX or FOLFIRI.
  • in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
  • as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Panitumumab is contraindicated in the following cases:

Interstitial pneumonitis, pulmonary fibrosis

at least one of
Interstitial pneumonia
Fibrosis of lung

Oxaliplatin

Oxaliplatin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: VECTIBIX Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈